menù
Phase: Phase II-III clinical trials
Principal Investigator: Prof. Vernieri Claudio
Main Facility: Medical Oncology 1
Drug: ARM 1: MK2870 + Pembrolizumab e Carboplatin/Paclitaxel/Pembrolizumab ARM 2: Carboplatin/Paclitaxel/Pembrolizumab + Adriamycin/Cyclophosphamide e Pembrolizumab
Phase: Phase III clinical trials
Principal Investigator: Dott.ssa Guadalupi Valentina
Main Facility: Genitourinary Medical Oncology
Drug: Sacituzumab Tirumotecan (MK-2870) vs Investigator’s Choice of Non-platinum Chemotherapy
Principal Investigator: Dr. Procopio Giuseppe
Drug: Belzutifan (120 mg qd) + Zanzalintinb (60 mg qd) versus Cabozantinb (60 mg qd)
Principal Investigator: Dr. Fumagalli Elena
Main Facility: Medical Oncology 2
Drug: Velzatinib (GSK6042981) versus Imatinib
Principal Investigator: Professor Filippi Andrea Riccardo
Main Facility: Radiation Oncology Unit
Drug: MK-1084
Principal Investigator: Dr. Lo Russo Giuseppe
Main Facility: Thoracic Oncology Unit
Drug: MK-1084 Pembrolizumab
Principal Investigator: Dott.ssa Verzoni Elena
Drug: Xaluritaming + Abiraterone versus Docetaxel, Cabazitaxel e Abiraterone
Principal Investigator: Dott. Occhipinti Mario
Drug: Tarlatamab (AMG 757)
Drug: Ifinatamab Deruxtecan (I-Dxd)(MK2400) 12mg/kg vs Docetaxel 75 mg/mq
Principal Investigator: Dr. Proto Claudia
Drug: Ifinatamab Deruxtecan (I-DXd)
Drug: Sotorasib, Pembrolizumab, Carboplatino, Pemetrexed
Principal Investigator: Dr. Pietrantonio Filippo
Main Facility: Gastrointestinal Oncology
Drug: Tislelizumab
Principal Investigator: Dr. Prelaj Arsela
Drug: NVL-655
Drug: MK2870 (sacituzumab tirumotecan) Pembrolizumab Chemotherapy
Drug: Opevesostat (MK-5684) + hormone replacement therapy (HRT) // abiraterone acetate or enzalutamide
Drug: PASRITAMIG (BISPECIFOC KLK-2 / CD3 ANTIBODY)
Main Facility: Medical Oncology 1 – Medical Oncology Unit: Melanoma
Drug: Brenetafusp, Nivolumab
Drug: Pembrolizumab MK-2870 (sacituzumab tirumotecan) Chemotherapy
Drug: V940
Principal Investigator: Associate Professor Licitra Lisa Francesca Linda
Main Facility: Medical Oncology 3 – Head and Neck Cancers
Drug: Amivantamab
Sign up for our newsletter to stay informed about news, events, and updates from the Institute
Subscribe